Loading
JMT203 is a monoclonal antibody from Shanghai JMT-Bio Inc., in registered phase 2 trials for non-small-cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer.
JMT203 is listed on ClinicalTrials.gov as an intervention in 2 registered phase 2 trials sponsored by Shanghai JMT-Bio Inc., in non-small-cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A monoclonal antibody, as described in the registry record.
1.JMT203 binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JMT203" OR ABSTRACT:"JMT203") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JMT203, not a curated reading list.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares CSPC Pharmaceutical Group, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Non-small-cell lung cancer and the tags pipeline, registry-only.